Allena Pharmaceuticals — Investor Presentation (June 2019)
27 slides from Allena Pharmaceuticals's investor presentation, Jun 4, 2019
Slide 1: Bringing First-in-Class Oral Enzyme Therapeutics to Patients with Rare and Severe Metabolic and Kidney Disorders
Bringing First-in-Class Oral Enzyme Therapeutics to Patients with Rare and Severe Metabolic and Kidney Disorders June 2019 Exhibit 99.2
Slide 2: Forward-Looking Statements
Allena Pharmaceuticals, Inc. These slides, and any accompanying presentation, contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue
Slide 3: Highlights – Pioneering Oral Enzyme Therapeutic Platform
Highlights – Pioneering Oral Enzyme Therapeutic Platform Significant Unmet Need in Oxalate and Urate Disorders Focused on rare and severe metabolic disorders that can cause kidney stones, damage the kidney, and potentially lead to CKD and ESRD Lead program in Enteric Hyperoxaluria (EH), a rare metab
Slide 4: Allena's Pipeline: First-in-Class Therapeutic Strategy for Oxalate and Urate Disorders
Product Indication Discovery Pre-Clinical Phase 1 Phase 2 Phase 3 Next Milestone Commercial Rights Reloxaliase Enteric hyperoxaluria 2H19: Topline data URIROX-1 Worldwide Systemic oxalosis* 2H19: Topline data Study 206 Worldwide Primary hyperoxaluria* (Orphan Designation) 2H19: Topline data Study 20
Slide 5: Hyperoxaluria is Characterized by Markedly Elevated Urinary Oxalate Levels
Hyperoxaluria is Characterized by Markedly Elevated Urinary Oxalate Levels Source: Illustration adapted from Coe, Fred. “Control of Urine Oxalate Excretion.” Kidneystones.uchicago.edu. University of Chicago, kidneystones.uchicago.edu/control-of-urine-oxalate-excretion . March 2017. Fecal Excretion G
Slide 6: Enteric Hyperoxaluria Patients Are a High Risk Population in Need of Treatment
Enteric Hyperoxaluria Patients Are a High Risk Population Who Are Identifiable by Physicians and in Need of Treatment There are no FDA approved pharmacological therapies to treat any form of hyperoxaluria Enteric GI malabsorptive conditions include: gastric bypass surgery, Crohn’s disease, ulcerativ
Slide 7: Risk of Renal Complications Rises with Higher Urinary Oxalate Levels
Risk of Renal Complications Rises with Higher Urinary Oxalate Levels: Reduction of UOx Improves Renal Outcomes Illustrative Diagram Sources: Robertson and Hughes, Scanning Microsc. 1993; Keddis Curr Opin Nephrol Hypertens. 2013; Robertson and Peacock, Nephron. 1980; Milliner, Kidney Int. 2006; Curha
Slide 8: Allena Initially Targeting Enteric Hyperoxaluria Patients with Underlying Malabsorptive GI Diseases
Allena Initially Targeting Enteric Hyperoxaluria Patients with Underlying Malabsorptive GI Diseases and Kidney Stones 4-year progression of disease 4.4M Estimated Patients with GI Malabsorptive Conditions with No Prior Kidney Stones or CKD Patients potentially at risk for enteric hyperoxaluria1 Kidn
Slide 9: Reloxaliase for the Treatment of Hyperoxaluria
Reloxaliase for the Treatment of Hyperoxaluria
Slide 10: Evolution of Reloxaliase Enteric Hyperoxaluria Program
Evolution of Reloxaliase Enteric Hyperoxaluria Program Preclinical Ph 1 Healthy Volunteers Ph 2 Open Label Ph 2 Randomized Controlled Ph 3 Randomized Controlled ✓ ✓ ✓ ✓ Initiated 1Q 2018 and 4Q 2018 Progressive Increase in Enzyme Activity Porcine Rhubarb Model Presented at AUA 2016 Porcine Western D
Slide 11: Study 713: Substantially Greater Reloxaliase Treatment Response in Enteric Population
Study 713: Substantially Greater Reloxaliase Treatment Response in Enteric Population 1. Beyond the primary endpoint analysis, all p-values are descriptive. Overall (n=67) Enteric (n=18) Key Endpoints: Reloxaliase vs. placebo ∆ p-value ∆ p-value Change in UOx (mg/24h) from baseline to week 4 -6.35 m
Slide 12: Study 713: Substantially Greater Reloxaliase Treatment Response in Enteric Population
Study 713: Substantially Greater Reloxaliase Treatment Response in Enteric Population *Beyond the primary endpoint analysis, all p-values are descriptive. Enteric Reloxaliase Enteric Placebo Change in TWA Urinary Oxalate (mg/24h) Baseline Urinary Oxalate (mg/24h) Change in TWA UOx Excretion vs. Base
Slide 13: Reloxaliase Generally Well-Tolerated in Clinical Trials to Date
Reloxaliase Generally Well-Tolerated in Clinical Trials to Date 1TEAE = Treatment emergent adverse events are defined as AEs with onset at the time of or following the first dose of treatment with study drug through 7 days after their last dose of study medication, or AEs starting before the start o
Slide 14: Unmet Need: Reduce Risk of Oxalate Damage to the Kidney in Patients with EH
Unmet Need: Reduce Risk of Oxalate Damage to the Kidney in Patients with EH and Elevated Urinary and Plasma Oxalate Source:1. Ermer T et al. Curr Opin Nephrol Hypertens. 2016; 25(4): 363–37. 2. Lumlertgul et al, Kidney Int Rep 2018; 3:1363-1372 Unmet Need: Reduce Risk of Oxalate Damage to the Kidney
Slide 15: Study 206: Reloxaliase Treatment of Adult and Pediatric Patients with Primary or Enteric Hyperoxaluria
Study 206: Reloxaliase Treatment of Adult and Pediatric Patients with Primary or Enteric Hyperoxaluria and Advanced CKD ('Basket' Study) Study Design: Open-label study of subjects ≥ 12yrs in PH or EH w/ hyperoxalemia Key Endpoint: Change from baseline in POx and 24h UOx excretion 1 x POx 2 x 24h PH:
Slide 16: Severe EH Patient Population with Decreased Renal Function, Transplant and Dialysis
Severe EH Patient Population with Decreased Renal Function, Transplant and Dialysis with Systemic Oxalosis Study Update: Enrolling subjects across multiple PH and EH subpopulations, 7 completed treatment, 4 EH shown below Piloting use of POx testing in a multicenter trial for potential expansion int
Slide 17: Reloxaliase Demonstrated a Robust Reduction in UOx and POx in Four EH Patients
Reloxaliase Demonstrated a Robust Reduction in UOx and POx in Four EH Patients with Hyperoxalemia ∆ = 1.4 µmol/L Crohn’s Disease Hemodialysis Baseline POx 40 µmol/L Fat Malabsorption CKD 3T UOx/Cr 210 POx 9.0 µmol/L Pancreatic Insufficiency Hemodialysis (failed KTx) Baseline POx 104 µmol/L Short Bow
Slide 18: Phase 3 Program Incorporates Key Learnings from Phase 2
Phase 3 Program Incorporates Key Learnings from Phase 2 Phase 3 Program Phase 2 Program Identified Phase 3 Patient Population Identified Pivotal Endpoint Identified Phase 3 Trial Design ü Identified Key Secondary Endpoints Enteric hyperoxaluria is a rare disease without available treatment ü Percent
Slide 19: Consistent Phase 2 Clinical Results in EH De-risk Phase 3 Program
Consistent Phase 2 Clinical Results in EH De-risk Phase 3 Program Consistent response in patients with Enteric Hyperoxaluria Patients with ≥ 50mg/24h baseline and screening UOx entry criteria for URIROX-1 Well tolerated, no SAEs Overall EH (n=5) Percent Change in UOx (%) Presented at ASN 2014 Presen
Slide 20: URIROX-1: Evaluate the Safety and Efficacy of Reloxaliase in Patients with Enteric Hyperoxaluria
URIROX-1: Evaluate the Safety and Efficacy of Reloxaliase in Patients with Enteric Hyperoxaluria Study Update: > 50% enrolled Pretreatment data on initial patient cohort demonstrates decreased variability from screening to baseline in 24h UOx No safety concerns identified in blinded data On target t
Slide 21: URIROX-2: Randomized Trial Design and Adaptive Strategy
Randomization 1:1 n≈400 RCT follow-up for minimum of 2 years Patient Population: Patients with enteric hyperoxaluria UOx ≥50 mg/d, history of kidney stones and eGFR ≥30 prior to screening Randomization stratified by: bariatric surgery vs. other enteric condition Endpoints for UOx Biomarker: Primary:
Slide 22: Reloxaliase Pivotal Program in Enteric Hyperoxaluria
1H 2018 2H 2018 1H 2019 2H 2019 1H 2020 2H 2020 Reloxaliase Pivotal Program in Enteric Hyperoxaluria Incorporates Consistent Biomarker Endpoints in Both Phase 3 Trials Follow subjects for a minimum of 2 years for post approval confirmation URIROX-1 in Enteric HO RCT x 4 weeks n=~124 Topline Data URI
Slide 23: Significant Progress in the Treatment of Oxalate Disorders
Significant Progress in the Treatment of Oxalate Disorders RNAi Whole bacteria Small molecules Reloxaliase Reloxaliase There are no FDA approved pharmacological therapies to treat any form of hyperoxaluria ~5K Primary 200-250K Enteric Therapeutic Approaches in Clinical Development Ecosystem of Stake
Slide 24: Study 206 Interim Data: Primary Hyperoxaluria Patients with Preserved Renal Function
Study 206 Interim Data: Primary Hyperoxaluria Patients with Preserved Renal Function Create table Percent Change in UOx (%) PH 2 UOx/Cr 109 mg/g PH 3 UOx/Cr 61 mg/g PH 2 UOx/Cr 79 mg/g Urinary Oxalate (UOx mg/d) was normalized to creatine g/day PH Subtype eGFR (mL/min/1.73m2) Baseline UOx/Cr (mg/g)
Slide 25: ALLN-346: Significant Opportunity in Gout Patients with Moderate-to-Severe CKD
ALLN-346: Significant Opportunity in Gout Patients with Moderate-to-Severe CKD Gout Market is Incompletely Served by Existing Therapies ~375,000 gout patients with moderate to severe CKD who have uncontrolled gout on urate lowering therapy (ULT)* Gout patients with renal impairment are not optimally
Slide 26: Execution of Clinical and Regulatory Milestones
Execution of Clinical and Regulatory Milestones YEAR TARGET MILESTONE STATUS 2018 1Q18 Initiate URIROX-1 ü 1Q18 Initiate Study 206, Phase 2 Study in PH and EH with Hyperoxalemia ü 2H18 Present ALLN-346 Animal Data New ü 2H18 Initiate URIROX-2 ü 2H18 Study 206 Interim Data Update ü 2019 1H19 File IND
Slide 27: Highlights – Pioneering Oral Enzyme Therapeutic Platform
Highlights – Pioneering Oral Enzyme Therapeutic Platform Significant Unmet Need in Oxalate and Urate Disorders Focused on rare and severe metabolic disorders that can cause kidney stones, damage the kidney, and potentially lead to CKD and ESRD Lead program in Enteric Hyperoxaluria (EH), a rare metab
Allena Pharmaceuticals — Investor Presentation (June 2019) on 6ix